IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 215.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,546 shares of the company’s stock after acquiring an additional 11,982 shares during the period. SG Americas Securities LLC’s holdings in IDEXX Laboratories were worth $8,812,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of IDXX. BlackRock Inc. grew its holdings in shares of IDEXX Laboratories by 2.3% in the first quarter. BlackRock Inc. now owns 8,699,360 shares of the company’s stock valued at $4,350,376,000 after purchasing an additional 196,360 shares in the last quarter. Moneta Group Investment Advisors LLC boosted its position in IDEXX Laboratories by 121,647.2% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock valued at $3,038,192,000 after buying an additional 7,441,162 shares during the period. Alliancebernstein L.P. grew its stake in shares of IDEXX Laboratories by 11.5% in the fourth quarter. Alliancebernstein L.P. now owns 3,240,710 shares of the company’s stock worth $1,322,080,000 after acquiring an additional 334,020 shares in the last quarter. Geode Capital Management LLC increased its position in shares of IDEXX Laboratories by 1.4% during the first quarter. Geode Capital Management LLC now owns 1,946,339 shares of the company’s stock worth $971,569,000 after acquiring an additional 26,197 shares during the period. Finally, Franklin Resources Inc. raised its stake in shares of IDEXX Laboratories by 13.3% in the fourth quarter. Franklin Resources Inc. now owns 1,367,547 shares of the company’s stock valued at $557,904,000 after acquiring an additional 160,145 shares in the last quarter. 86.85% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on IDXX shares. Morgan Stanley boosted their target price on IDEXX Laboratories from $590.00 to $600.00 and gave the stock an “overweight” rating in a research note on Thursday, August 3rd. Atlantic Securities downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $610.00 price objective for the company. in a research report on Wednesday, August 2nd. JPMorgan Chase & Co. boosted their target price on IDEXX Laboratories from $550.00 to $600.00 and gave the company an “overweight” rating in a report on Wednesday, August 2nd. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $525.00 to $500.00 and set a “hold” rating on the stock in a research note on Friday. Finally, StockNews.com assumed coverage on IDEXX Laboratories in a research note on Thursday, August 17th. They issued a “buy” rating for the company. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $571.67.

Insider Buying and Selling

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 13,424 shares of IDEXX Laboratories stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $512.01, for a total transaction of $6,873,222.24. Following the completion of the transaction, the chief executive officer now owns 72,925 shares in the company, valued at $37,338,329.25. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, EVP Michael Lane sold 16,027 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $510.00, for a total value of $8,173,770.00. Following the completion of the transaction, the executive vice president now owns 4,034 shares of the company’s stock, valued at $2,057,340. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jonathan Jay Mazelsky sold 13,424 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $512.01, for a total transaction of $6,873,222.24. Following the sale, the chief executive officer now owns 72,925 shares in the company, valued at approximately $37,338,329.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,360 shares of company stock valued at $26,743,411. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Trading Down 2.5 %

NASDAQ:IDXX opened at $450.69 on Friday. The stock has a market capitalization of $37.41 billion, a price-to-earnings ratio of 47.84, a PEG ratio of 2.66 and a beta of 1.20. IDEXX Laboratories, Inc. has a 1 year low of $317.06 and a 1 year high of $564.73. The stock has a fifty day moving average price of $511.69 and a two-hundred day moving average price of $490.61. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.89 and a current ratio of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 1st. The company reported $2.67 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.24. The company had revenue of $943.63 million for the quarter, compared to analyst estimates of $927.84 million. IDEXX Laboratories had a net margin of 22.52% and a return on equity of 104.84%. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 9.82 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.